PHARMACY **BENEFACT**

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS®

April 1, 2025 full updates for the *Alberta Drug Benefit List (ADBL), Alberta Human Services Drug Benefit Supplement (HSDBS)* and *Palliative Coverage Drug Benefit Supplement (PCDBS)*

Please be advised that the annual April 1, 2025 Full Updates to the *ADBL*, *HSDBS* and the *PCDBS*, including the Summary of Changes have been posted online at **www.ab.bluecross.ca/dbl/publications.php**

Drug products removed from the *ADBL* as the manufacturer *did not submit* a price to the annual *Alberta Price Confirmation (APC)*

As per the Alberta Price Policy, manufacturers with drug products currently listed on the *ADBL* were invited to re-quote the price of drug product(s) for continual listing. Please be advised that the following drug products will no longer be listed or eligible for payment under Alberta government-sponsored drug programs effective **April 1, 2025**, as these manufacturers have chosen not to confirm pricing.


All drug products scheduled to be removed from the *ADBL* have been identified as having therapeutic alternatives. *Effective* **April 1, 2025**, the listed products will no longer be a benefit and will not be considered for coverage by Special Authorization. A **30-day transition period** will be applied to allow physicians, pharmacists and patients directly affected by these changes sufficient time to transition to another drug therapy as appropriate and, as of **May 1, 2025**, claims will no longer pay for these products.

Patients impacted by the removal of these drug products as covered benefits for Alberta government-sponsored drug programs are encouraged to discuss therapeutic alternatives with their health care provider(s).

DIN/NPN	Product description
00080062704	JAMP-POTASSIUM CHLORIDE ER 8 MEQ EXTENDED-RELEASE CAPSULE
00002367408	CLOXACILLIN 500 MG/VIAL INJECTION
00002367416	CLOXACILLIN 1 G/VIAL INJECTION

Drug products removed from the ADBL due to discontinuation by the manufacturer

The Alberta government-sponsored drug programs previously covered the following drug products; however, notification of discontinuation has been received from the manufacturers. Effective **April 1, 2025**, the listed products will no longer be a benefit and will not be considered for coverage by Special Authorization. A **30-day transition period** will apply and, as of **May 1, 2025**, claims will no longer pay for these products. Patients impacted by the discontinuation of these drug products as covered benefits for Alberta government-sponsored drug programs are encouraged to discuss therapeutic alternatives with their health care provider(s).







continued from previous page

DIN	Product description
00002432463	LODALIS 3.75 G ORAL POWDER PACKET
00002489058	RIVA-DAPSONE 100 MG TABLET
00000657204	STIEVA-A 0.01% TOPICAL CREAM

For a summary of all updates, please refer to the Summary of Changes for highlights of products and pricing changes.

Please note that the online *interactive Drug Benefit List (iDBL)* is available at **www.ab.bluecross.ca/dbl/idbl_main1.php**; this is a near real-time application and as such, contains the most up-to-date information.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area) 403-294-4041 (Calgary and area) 1-800-361-9632 (toll free) FAX 780-498-8406 (Edmonton and area) FAX 1-877-305-9911 (toll free)



Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct-bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. BE011-0054.1242 2025/03